Alpha thalassemia

Alpha thalassemia
Graham Beards · CC BY-SA 4.0 · source
Name	Alpha thalassemia
Field	Hematology
Symptoms	Anemia, jaundice, splenomegaly
Complications	Hydrops fetalis, heart failure, iron overload
Onset	Congenital
Causes	Deletions or mutations of HBA1 and HBA2
Diagnosis	Complete blood count, hemoglobin electrophoresis, genetic testing
Treatment	Transfusion, chelation, bone marrow transplant

Alpha thalassemia is an inherited hemoglobinopathy caused by decreased or absent synthesis of alpha globin chains due to deletions or point mutations affecting HBA1 and HBA2. It produces a spectrum of severity from asymptomatic carrier states to lethal fetal hydrops with profound anemia, and overlaps clinically with other inherited red cell disorders. Management involves supportive care, transfusion strategies, iron chelation, and definitive therapies in specialized centers.

Signs and symptoms

Clinical manifestations range from none to life-threatening. Carriers with one gene deleted typically have silent presentation identified incidentally during screening for Sickle cell disease, Thalassemia major, or prenatal testing tied to programs in United Kingdom, United States, and Australia. Individuals with two-gene deletions may present with microcytosis and mild anemia prompting referral to hematology services associated with institutions such as Mayo Clinic, Johns Hopkins Hospital, or Great Ormond Street Hospital. Three-gene deletion carriers often develop hemoglobin H disease characterized by moderate to severe hemolytic anemia, jaundice, splenomegaly, growth delay seen in pediatric clinics like Boston Children's Hospital, and need for intermittent transfusions as observed in cohorts followed at King's College Hospital. Four-gene deletion causes Hb Bart hydrops fetalis with edema, heart failure, intrauterine demise or perinatal mortality frequently managed by perinatal teams at Fetal Medicine Unit, University College London and referral centers in Singapore General Hospital.

Genetics and pathophysiology

Alpha chain production is encoded by two linked genes on chromosome 16, HBA1 and HBA2, whose loss reduces alpha:beta chain ratios and leads to formation of abnormal tetramers. Large deletions mediated by homologous recombination between repeated sequences produce common genotypes described in population studies from Southeast Asia, Mediterranean Basin, and West Africa reported by research groups at Harvard Medical School and University of Cambridge. Point mutations and regulatory defects identified by laboratories at Institut Pasteur and Karolinska Institutet also cause nondeletional alpha thalassemia. Imbalanced globin synthesis results in precipitation of excess beta chains (or gamma chains in fetal life) forming inclusion bodies, ineffective erythropoiesis with expansion of marrow observed in patients treated at Massachusetts General Hospital, and extravascular hemolysis with increased erythrophagocytosis described in reviews from Royal College of Physicians. Molecular pathophysiology informs prenatal counseling programs in centers like Karolinska University Hospital and Sheba Medical Center.

Diagnosis

Diagnosis integrates hematologic testing, hemoglobin analysis, and molecular assays. Initial screening often occurs via complete blood count abnormalities flagged by clinical laboratories at Cleveland Clinic and hemoglobin electrophoresis used routinely at Molecular Diagnostics Laboratory, University of Oxford. High-performance liquid chromatography and capillary electrophoresis may be performed in reference centers such as Mayo Clinic Laboratories; however, fetal and newborn presentations often require DNA-based deletion testing by laboratories at Addenbrooke's Hospital or sequencing approaches developed at Broad Institute. Prenatal diagnosis uses chorionic villus sampling or amniocentesis in specialized fetal medicine units at UCSF and Imperial College Healthcare NHS Trust. Differential diagnosis includes iron deficiency identified by assays from World Health Organization programs and concomitant conditions screened by multidisciplinary teams at Royal Children's Hospital Melbourne.

Management and treatment

Management follows severity: silent carriers need reassurance while symptomatic patients receive coordinated care in hematology centers such as St. Jude Children's Research Hospital and Fred Hutchinson Cancer Center. Regular transfusion regimens for severe disease are supervised by transfusion services like those of American Red Cross and incorporate iron chelation with agents used in clinical trials at National Institutes of Health and pharmaceutical research at Novartis and Shire. Splenectomy is considered in refractory hemolysis per guidelines from British Society for Haematology. Curative intent options include hematopoietic stem cell transplantation performed at transplant centers such as Seattle Children's Hospital and emerging gene therapy trials coordinated by groups at University of Pennsylvania and CRISPR Therapeutics. Perinatal management for affected pregnancies involves multidisciplinary teams at Guy's and St Thomas' NHS Foundation Trust and delivery planning in tertiary care obstetric units.

Epidemiology

Prevalence is highest in malaria-endemic regions due to historical selective advantage recorded in studies from Greece, Thailand, Nigeria, and India and synthesized in population genetics work at University College London. Carrier frequencies reach significant proportions in parts of Southeast Asia and the Mediterranean, reflected in newborn screening programs run by public health authorities in Cyprus, Sardinia, and Malta. Migration patterns have led to increased recognition in metropolitan centers such as London, New York City, and Toronto monitored by public health agencies like Centers for Disease Control and Prevention and Public Health England.

History and research developments

Descriptions of microcytic anemias predate molecular genetics and were refined by clinicians in the 20th century at institutions including Johns Hopkins University and University of Bologna. The genetic basis was elucidated with chromosomal mapping and DNA techniques advanced at Cold Spring Harbor Laboratory and EMBL. Landmark developments include population screening programs established in Cyprus and gene-editing trials initiated by consortia at University of California, San Francisco and Institut de Recherche Clinique. Ongoing research spans genome editing, novel chelators, and prenatal therapeutics pursued at centers like Karolinska Institutet, Dana-Farber Cancer Institute, and industry collaborations with GSK and Bluebird Bio.

Category:Hemoglobinopathies